Cardamonin Suppresses the Proliferation of Colon Cancer Cells by Promoting β-Catenin Degradation

Seoyoung Park,a Jung sug Gwak,a Seung Jin Han,b and Sangtack Oh*a,d

a Department of Advanced Fermentation Fusion Science & Technology, Kookmin University; Seoul 136–702, Republic of Korea; and b Department of Biological Sciences, Inje University; Gimhae, Gyeongnam 621–749, Republic of Korea.

Received February 20, 2013; accepted March 23, 2013; advance publication released online March 29, 2013

Aberrant accumulation of intracellular β-catenin and subsequent activation of β-catenin response transcription (CRT) in intestinal epithelial cells is a frequent early event during the development of colon cancer. Here we show that cardamonin, a chalcone isolated from Aplinia katsunodai Hayata, inhibited CRT in SW480 colon cancer cells that carry inactivating mutation in the adenomatous polyposis coli (APC) gene. Cardamonin also down-regulated intracellular β-catenin levels in SW480 cells without affecting its mRNA levels. Interestingly, pharmacological inhibition of the proteasome prevented the cardamonin-induced down-regulation of β-catenin. In addition, cardamonin suppressed the expression of cyclin D1 and c-myc, which are known β-catenin/T cell factor (TCF)-dependent genes. Moreover, cardamonin inhibited the growth of various colon cancer cells and induced G2/M cell cycle arrest in SW480 colon cancer cells. These findings indicate that cardamonin is a potential chemotherapeutic agent against colon cancer.

Key words cardamonin; colon cancer; β-catenin; protein degradation

Wnt/β-catenin signaling plays important role in cellular proliferation, morphology, motility, fate, axis formation, and organ development.1–3) Intracellular β-catenin levels, which are regulated by phosphorylation-dependent proteasomal degradation, are key regulators of this signaling pathway. Casein kinase 1 (CK1) and glycogen synthase kinase-3β (GSK-3β), which form a complex with the scaffolding protein Axin and the tumor suppressor protein adenomatous polyposis coli (APC), sequentially phosphorylate β-catenin at Ser45, Thr41, Ser37, and Ser33.4,5) Phosphorylated β-catenin is then recognized by the F-box β-transducin repeat-containing protein (β-TrCP), a subunit of the ubiquitin ligase complex, leading to its ubiquitin-dependent proteolysis.6,7) Therefore, intracellular β-catenin is usually maintained at low levels in normal cells. However, in the presence of Wnt ligands, the activity of the CK1/GSK-3β/APC/Axin destruction complex is negatively regulated; this results in the stabilization of cytoplasmic β-catenin.

Colorectal cancer is the most prevalent type of cancer and the second leading cause of cancer-related mortality in Western countries.8,9) The association between aberrant Wnt/β-catenin signaling and cancer, particularly colorectal cancer, has been well documented.10) Mutations in the APC gene have been identified in patients with familial adenomatous polyposis coli (FAP) and sporadic colorectal tumors.10,11) In addition, mutations in the β-catenin gene, affecting its N-terminal phosphorylation motif, have been observed in patients with colorectal cancer.11) These mutations result in β-catenin accumulation in the nucleus, where it forms a complex with members of the T-cell factor/lymphocyte enhancer factor (TCF/LEF) transcription factor family. This leads to the enhanced expression of Wnt/β-catenin-responsive genes, including cyclin D1, myc, matrix metalloproteinase-7, and peroxisome proliferator-activated receptor (PPAR)-δ, which play important roles in colorectal tumorigenesis.12–15) Thus, suppressing abnormally activated β-catenin response transcription (CRT) is a potential therapeutic approach for the chemoprevention and treatment of colon cancers.

In the present study, we demonstrated that cardamonin significantly inhibits the Wnt/β-catenin pathway by down-regulating intracellular β-catenin in colon cancer cells, thereby inducing G2/M cell cycle arrest and suppressing the proliferation of colon cancer cells.

MATERIALS AND METHODS

Cell Cultures, Transfection, and Plasmids SW480, DLD-1, HCT116, and LS174T colon cancer cell lines were obtained from the American Type Culture Collection and maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 120 µg/mL penicillin, and 200 µg/mL streptomycin. Transfection was performed using Lipofectamine 2000 (Invitrogen, U.S.A.) according to the manufacturer’s instructions. The cyclin D1 promoter region was amplified by polymerase chain reaction (PCR) and then inserted into a pRL-null reporter plasmid (Promega, U.S.A.). The pTOPFlash and pFOPFlash reporter plasmids were obtained from Upstate Biotechnology and the pCMV-RL plasmid was purchased from Promega.

Western Blotting Cytosolic fractions were prepared as described previously.16) Whole lysates were prepared using NP40 lysis buffer. Proteins were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis in a 4–12% gradient gel (Invitrogen) and transferred to nitrocellulose membranes. The membranes were blocked using Odyssey blocking buffer (Li-Cor) and probed with anti-β-catenin (BD Transduction Laboratories), anti-cyclin D1, anti-c-myc (Santa Cruz Biotechnology), and anti-actin antibodies (Sigma). After washing with Tris-buffered saline plus Tween (TBS-T), the blots were incubated with fluorochrome-conjugated secondary antibodies, IRDye® 800CW Secondary Antibodies (Li-Cor). Membranes were then imaged using Odyssey Imaging System (Li-Cor).

RNA Extraction and Semiquantitative Reverse Transcription (RT)-PCR Total RNA was isolated using TRIzol reagent (Invitrogen) in accordance with the manufacturer’s
instructions. cDNA synthesis, reverse transcription, and PCR were performed as previously described.17 Amplified DNA was mixed with Loading Star (DYNEBIO) and separated using 2% agarose gels.

Cell Viability Assay Cells were inoculated into 96-well plates and treated with cardamonin for 48 h. Cell viability in each treated sample was measured in triplicate using the CellTiter-Glo assay kit (Promega), according to the manufacturer's instructions.

Cell Cycle Analysis SW480 cells were treated with cardamonin for 24 h. Cells were then collected, washed with cold phosphate buffered saline (PBS), and fixed in 70% ethanol at 4°C overnight. They were then centrifuged at 2000 rpm for 5 min, resuspended in PBS, and incubated with propidium iodide (100 µg/mL) and RNase A (50 µg/mL) at room temperature for 30 min in the dark. Cells were then analyzed using a FACSCalibur flow cytometer (Becton–Dickinson).

RESULTS

Cardamonin Induces β-Catenin Down-Regulation in SW480 Colon Cancer Cells To investigate the effect of cardamonin, 2′,4′-dihydroxy-6-methoxychalcone (Fig. 1A), on CRT in colon cancer cells, SW480 colon cancer cells, which carry truncating mutations in the APC gene that cause constitutive activation of CRT, were transfected with TOPFlash plasmid, a synthetic β-catenin/Tcf-dependent firefly luciferase reporter. Treatment of the transfected SW480 cells with different concentrations of cardamonin produced a dose-dependent decrease in CRT (Fig. 1B). In contrast, cardamonin did not affect the activity of FOPFlash, a negative control reporter with mutated β-catenin/Tcf binding elements, in SW480 cells (Fig. 1B).

In Wnt/β-catenin signaling, CRT is largely dependent on the level of intracellular β-catenin. Therefore, in order to assess whether cardamonin affects intracellular β-catenin levels, we performed western blot analysis using an anti-β-catenin antibody to quantify cytoplasmic β-catenin in cardamonin-treated SW480 colon cancer cells. As shown in Fig. 1C, cardamonin down-regulated cytoplasmic β-catenin levels in a dose-dependent manner, which is consistent with results from reporter assay. These results suggest that cardamonin suppresses CRT by down-regulating intracellular β-catenin levels in SW480 colon cancer cells.

Cardamonin Promotes Proteasome-Mediated β-Catenin Degradation Since cardamonin causes a reduction in the intracellular β-catenin level, we then examined whether cardamonin affects β-catenin mRNA levels using semiquantitative RT-PCR. In contrast with β-catenin protein levels, mRNA expression of β-catenin was not altered by any of the cardamonin concentrations used (Fig. 2A), suggesting that cardamonin inhibits the Wnt/β-catenin pathway by down-regulation of β-catenin protein levels rather than repression of β-catenin gene expression. Previous studies have demonstrated that intracellular β-catenin levels are regulated by a proteasomal degradation pathway.19 Therefore, we used MG-132, a proteasome inhibitor, to investigate the involvement of the proteasome in cardamonin-mediated β-catenin down-regulation. As shown in Fig. 2B, treatment of SW480 colon cancer cells with cardamonin consistently resulted in the down-regulation of cytoplasm β-catenin levels; however, the addition of MG-132 inhibited this cardamonin-mediated β-catenin down-regulation. These results indicate that cardamonin induces proteasome-mediated degradation of intracellular β-catenin in SW480 cells.

Cardamonin Suppresses the Expression of β-Catenin-Dependent Genes Given that cardamonin down-regulates intracellular β-catenin levels, we then examined the effect of cardamonin on the expression of β-catenin-dependent genes in SW480 colon cancer cells. To this end, we transfected SW480 cells with a reporter construct, in which luciferase expres-
sion was controlled by the cyclin D1 promoter that contains a β-catenin/TCF-4 responsive region. The cells were then incubated with various concentrations of cardamonin. As shown in Fig. 3A, cardamonin inhibited cyclin D1 promoter activity in SW480 cells. We also examined cyclin D1 protein level in cardamonin-treated SW480 cells, and observed a dose-dependent decrease in these protein levels in response to cardamonin (Fig. 3B), which is consistent with our cyclin D1 promoter results. Moreover, the expression of c-myc, a known downstream target of β-catenin, was significantly reduced in SW480 colon cancer cells following incubation with cardamonin (Fig. 3B).

**Cardamonin Inhibits Proliferation of Various Colon Cancer Cells**

Previous studies have reported that the specific disruption of β-catenin function by antisense oligonucleotides or small interference RNA suppresses the proliferation of cancer cells in vitro as well as tumor growth in a xenograft mouse model. Since cardamonin promotes β-catenin degradation, we hypothesized that cardamonin also inhibits the growth of colon cancer cells. Therefore, we examined the effect of cardamonin on the proliferation of various colon cancer cells. As shown in Fig. 4A, cardamonin efficiently inhibited the growth of CRT-positive colon cancer cells (SW480, DLD-1, HCT116, and LS174T) in a concentration-dependent manner. We then investigated the possible mechanism responsible for inhibiting colon cancer cell growth in response to cardamonin by determining cell cycle distribution using propidium iodide staining followed by flow cytometry analysis. When SW480 cells were incubated with cardamonin, the population of cells in the G2/M phase increased from 18.55% to 35.42% as compared with the vehicle control (Fig. 4B). These results suggest that cardamonin suppresses the growth of SW480 colon cancer cells by inducing G2/M cell cycle arrest.

**DISCUSSION**

Cardamonin exhibits antitumor properties by modulating cellular signal transduction pathways in several types of cancers. Qin et al. observed that cardamonin exerts preventive activity against multiple myeloma through blocking the nuclear factor-kappa B (NF-κB) pathway. Studies have also reported that cardamonin sensitizes tumor cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) through CCAAT/enhancer binding protein homologous protein (CHOP)-mediated up-regulation of death receptor. Additionally, Park et al. recently found that cardamonin inhibits the invasion of cancer cells by suppressing transglutaminase-2 expression and inhibiting its activity. In this study, we demonstrated, for the first time, that cardamonin suppresses the proliferation of colon cancer cells by promoting the degradation of intracellular β-catenin, which is abnormally accumulated in colon cancer cells.

Two APC-dependent pathways, an APC/Axin-dependent...
pathway and an APC/Siah-1-dependent pathway, are predominantly involved in the regulation of \( \beta \)-catenin protein stability. In the APC/Axin-dependent pathway, the APC/Axin complex facilitates the CK1/GSK-3\( \beta \)-mediated N-terminal phosphorylation of \( \beta \)-catenin, leading to its degradation.\(^4,5\) In the APC/Siah-1-dependent pathway, the carboxyl terminus of APC interacts with Siah-1, which recruits the ubiquitination complex and promotes the degradation of \( \beta \)-catenin.\(^26\) On the other hand, the results of the present study showed that cardamonin promotes the degradation of \( \beta \)-catenin in SW480 cells, which are APC-mutant colon cancer cells, suggesting that APC is not required for \( \beta \)-catenin degradation by cardamonin. We will further investigate the mechanism of cardamonin-stimulated \( \beta \)-catenin degradation in future studies.

Several natural compounds that inhibit the function of pathogenic \( \beta \)-catenin have been identified. Curcumin, which is found in turmeric, was shown to induce the caspase-3-mediated cleavage of \( \beta \)-catenin\(^27\) and its natural derivatives were shown to repress \( \beta \)-catenin response transcription (CRT) through down-regulation of the transcriptional coactivator p300.\(^28\) Quercetin, a representative flavonol, was shown to suppress Wnt/\( \beta \)-catenin signaling by reducing \( \beta \)-catenin and Tcf4 nuclear levels.\(^29\) In this study, we found that cardamonin promotes intracellular \( \beta \)-catenin degradation through an APC-independent mechanism, and as a result suppresses the expression of cyclin D1 and c-myc, which play important roles in tumorigenesis and cell cycle progression.

In conclusion, we examined the anticancer effect of cardamonin on colon cancer cells, and we observed that cardamonin promotes the degradation of intracellular \( \beta \)-catenin, thereby inhibiting the proliferation of colon cancer cells. Therefore, our findings could facilitate the development of new chemopreventive or antineoplastic agents for colon cancer.

Acknowledgments This work was supported by the Basic Science Research Program (2012R1A2A2A01002941) and the Fundamental Technology Program (2012M3A9B2028335) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.
REFERENCES